Eligo Bioscience
France - ParisBiotechnology
Focus: Eligo Bioscience is a biotech company specializing in protein-based nanodelivery vectors and bacteriophage-derived therapeutics, positioned in the emerging field of engineered biology. The company is Paris-based and appears to be in early-stage development.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Open Jobs
5+4 this month
Stable — net +4 jobs in 30d
4 added, 0 removed. Backfill posture.
Should You Work at Eligo Bioscience?
AI assessmentEligo represents a high-risk, high-reward early-stage opportunity best suited for scientists willing to bet on novel platform technology with limited near-term visibility.
Why Work Here
- Opportunity to work on cutting-edge bacteriophage and nanodelivery technology platforms with significant unmet potential in synthetic biology
- Early-stage biotech offers equity upside and hands-on influence on company direction before scaling
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Eligo Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.